Clinical trials: Throat Carcinoma
Nasopharyngeal Carcinoma (NPC)
Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.
The objective of this study is to examine the potential impact of the treatment before, during, and/or after radiotherapy on the brain in patients with nasopharyngeal carcinoma (NPC) using Multiplex (MTP) MR imaging sequence…
- Trial name
- NPC (NCT07011329)
- Testing
- Changes in the brain MTP parameters after radiotherapy
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hubei Cancer Hospital
Oropharyngeal Neoplasms
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
The purpose of this study is to determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.
- Trial name
- NCT00251381
- Testing
- Cetuximab
- Where
- 18 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Trial Form Support S.L.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Nasopharyngeal Carcinoma
Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to provide a more reasonable basis for clinical…
- Trial name
- NCT02293356
- Testing
- Nimotuzumab Injection
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma, Recurrent or Metastatic
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by…
- Trial name
- NCT05294172
- Testing
- KL-A167, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 295 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Drug Use for Unapproved Schedule
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug
PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report: Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation…
- Trial name
- NCT03656965
- Testing
- Acyclovir 800 MG, Radiotherapy and chemotherapy
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Nasopharyngeal Carcinoma (NPC)
SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC
This is an investigator-initiated, single-center clinical trial designed to evaluate the feasibility of [68Ga]Ga-DOTA-TOC positron emission tomography (PET) scan in patients with Epstein-Barr virus (EBV) related nasopharyngeal…
- Trial name
- NACASOR (NCT06982300)
- Testing
- [68Ga]Ga-DOTA-TOC PET imaging
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Nasopharyngeal Carcinoma
Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer
The purpose of this study is to investigate whether reducing both the dose and the irradiated volume of cervical prophylactic irradiation in patients with nasopharyngeal cancer can maintain efficacy while decreasing toxicity.
- Trial name
- NCT06775756
- Testing
- IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Cancer, Chemotherapy
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to chemo-radiotherapy could further decrease the rate of disease progression and improve the…
- Conditions
- Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
- Trial name
- NCT04453826
- Testing
- Camrelizumab plus chemo-radiotherapy, Chemo-radiotherapy alone
- Where
- 6 sites in China
- Volunteers
- 388 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
The investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. Furthermore, the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by…
- Trial name
- NCT06442709
- Testing
- Tocilizumab Asprin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Hospital of Nantong University
Adenocarcinoma of the Esophago-gastric Junction
Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer
The objective of the study is comparison of the efficacy and safety of palliative therapy with single-dose brachytherapy or selfexpanding metal stents (SEMS) in malignant dysphagia resulting from adenocarcinoma of the…
- Trial name
- BRASTEGAC (NCT01786278)
- Testing
- Brachytherapy, Endoscopic stenting
- Where
- 2 sites in Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Lublin
Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
This phase II trial is studying how well giving bortezomib together with gemcitabine works in treating patients with recurrent or metastatic nasopharyngeal cancer.
- Trial name
- NCT00305734
- Testing
- bortezomib, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC)
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in southern China and Southeast Asia. While infection with Epstein-Barr Virus (EBV) is believed to be necessary for the development of NPC, non-viral…
- Trial name
- NCT01182909
- Where
- Taiwan
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Far Eastern Memorial Hospital
Nasopharyngeal Carcinoma
Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to examine the efficacy of maintenance chemotherapy for the treatment of metastatic nasopharyngeal carcinoma. Participants will be randomized to 3 arms.
- Trial name
- NCT02944708
- Testing
- Conventional chemotherapy, Maintenance chemotherapy 1, Maintenance chemotherapy 2
- Where
- 14 sites in China, Singapore and 1 more
- Volunteers
- 384 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Nasopharyngeal Carcinoma, Early Diagnosis of Cancer
Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma is one of the most common malignant tumors in China, with the progress of radiochemical comprehensive treatment, early stage The 5-year survival rate of nasopharyngeal cancer is more than 95%.
- Trial name
- NCT06367049
- Testing
- Methylation-specific PCR
- Where
- China
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06248840
- Testing
- Intermittent Oral-esophageal Tube Feeding, nasogastric tube feeding
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zeng Changhao
Nasopharyngeal Carcinoma
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
To evaluate the efficacy and toxicity of Nimotuzumab combined with VMAT in the treatment of elderly patients with nasopharyngeal carcinoma (> 70 years old), and to provide high-level clinical evidence for the optimal treatment of…
- Trial name
- NCT03915132
- Testing
- Nimotuzumab, VMAT
- Where
- China
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma (NPC)
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
This multicenter, open-label, randomized Phase III trial evaluates intensity-modulated proton therapy (IMPT) versus intensity-modulated photon radiotherapy (IMRT) in patients with newly diagnosed, high-risk, locoregionally…
- Trial name
- NCT07340515
- Testing
- Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT), Cisplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Man Hu
Nasopharyngeal Carcinoma
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC).
- Trial name
- NCT03097939
- Testing
- Ipilimumab, Nivolumab
- Where
- Singapore
- Volunteers
- 113 people
- Sponsor
- National Cancer Centre, Singapore
Recurrent Nasopharyngeal Carcinoma
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial
- Trial name
- NCT06228079
- Testing
- Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen
- Where
- 7 sites in China
- Volunteers
- 176 people
- Sponsor
- Eye & ENT Hospital of Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.